(AHMEDABAD, INDIA), February 17, 2010 – Today, the Dishman Group announced the formation of a strategic alliance with Codexis, Inc. a California based biotechnology company. This strategic partnership covers the use of Codexis’ proprietary enzymatic biocatalysis technology for the manufacture of building blocks, intermediates and APIs for innovator pharmaceutical companies. Dishman will be a preferred contract manufacturer for Codexis and will be able to offer the technology to its own customers. In addition, the companies will work exclusively on certain select accounts.
Codexis offers a wide selection of enzymes for the pharmaceutical synthesis of chiral compounds. With the majority of today’s drugs containing at least one chiral centre, this technology is directed at the very heart of pharmaceutical manufacture. In comparison to traditional chemical synthesis, this technology offers a number of significant advantages: cost reduction compared with conventional complex transformations as a result of telescoped processes, increased specificity gives improved yields and often improved impurity profiles, significant reduction in environmental impact through reduce use of organic solvents and reduced energy processes.
This alliance will benefit Codexis and its customers by enabling Codexis to offer production of both intermediates and final APIs in Dishman’s world-class manufacturing asset base. “We are delighted to be working with Codexis on this innovative technology. It adds another dimension to the already extensive portfolio of services offered by the Dishman Group. Our customers will benefit from cheaper, cleaner, greener processes manufactured in a low cost environment, a significant differentiator given today’s regulatory and market conditions ” said Nick Green, President Dishman CRAMS.
Profiles
Codexis, Inc. is a leading provider of optimized biocatalysts that make existing industrial processes faster, cleaner and more efficient than current methods and have the potential to make new industrial processes possible at commercial scale. Codexis has commercialized its biocatalysts in the pharmaceutical industry and is developing biocatalysts for use in producing advanced biofuels under a multi-year research and development collaboration. The company is also using its technology platform to pursue biocatalyst-enabled solutions in other bioindustrial markets, including carbon management, water treatment and chemicals.
Dishman Group (www.dishmangroup.com) is a global outsourcing partner for the pharmaceutical industry offering a portfolio of development, scale-up and manufacturing services. Dishman Group improves its customers businesses by providing a range of development and manufacturing solutions at locations in Europe (CARBOGEN AMCIS), China and India.
Visit Dishman at InformEx Feb 16-19, stand no. 1836
